GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axcella Health Inc (OTCPK:AXLA) » Definitions » PB Ratio

Axcella Health (Axcella Health) PB Ratio : (As of May. 04, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Axcella Health PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-04), Axcella Health's share price is $0.4009. Axcella Health's Book Value per Share for the quarter that ended in Jun. 2023 was $-0.77. Hence, Axcella Health's PB Ratio of today is .

The historical rank and industry rank for Axcella Health's PB Ratio or its related term are showing as below:

During the past 6 years, Axcella Health's highest PB Ratio was 45.00. The lowest was 0.00. And the median was 0.00.

AXLA's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.5
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Axcella Health's average Book Value Per Share Growth Rate was -117.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -72.10% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Axcella Health was -72.10% per year. The lowest was -72.10% per year. And the median was -72.10% per year.

Back to Basics: PB Ratio


Axcella Health PB Ratio Historical Data

The historical data trend for Axcella Health's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axcella Health PB Ratio Chart

Axcella Health Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PB Ratio
Get a 7-Day Free Trial - 1.54 2.59 3.72 5.79

Axcella Health Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.49 - 5.79 48.58 -

Competitive Comparison of Axcella Health's PB Ratio

For the Biotechnology subindustry, Axcella Health's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axcella Health's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axcella Health's PB Ratio distribution charts can be found below:

* The bar in red indicates where Axcella Health's PB Ratio falls into.



Axcella Health PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Axcella Health's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2023)
=0.4009/-0.766
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Axcella Health  (OTCPK:AXLA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Axcella Health PB Ratio Related Terms

Thank you for viewing the detailed overview of Axcella Health's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Axcella Health (Axcella Health) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 1270, Littleton, MA, USA, 01460
Axcella Health Inc a biotechnology company focused on treating complex diseases and improve health using endogenous metabolic modulator, or EMM, compositions. Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. The company's pipeline includes lead therapeutic candidates, AXA1665 for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125 for non-alcoholic steatohepatitis.
Executives
Paul Fehlner officer: Senior Vice President, CIPO C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
William Hinshaw director, officer: President and CEO C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
L.p. Fpa, 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Fpa General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Societe Des Produits Nestle S.a. 10 percent owner AVENUE NESTLE 55, VEVEY V8 CH-1800
Flagship Pioneering Inc. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Torben Straight Nissen director C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Robert L. Rosiello director 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Margaret Koziel officer: Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Michael Rosenblatt director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martin Hendrix director C/O PROMETHEUS BIOSCIENCES, INC., 9410 CARROLL PARK DRIVE, SAN DIEGO CA 92121
Paul J Sekhri director C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
David R Epstein director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Robert Crane officer: Chief Financial Officer 101 CONVENTION CENTER DRIVE SUITE 310, LAS VEGAS NV 89109